Evunzekibart

Evunzekibart is a human monoclonal antibody and a Fcγ receptor-dependent 4-1BB (CD137/TNFRSF9) agonist. Evunzekibart exerts potent antitumor immune activity by selectively activating effector T cells and NK cells in the tumor microenvironment. Evunzekibart is being investigated as a monotherapy or in combination with anti-PD-1/PD-L1 agents for the treatment of advanced solid tumors.

Methods: Human NK cells were pre-stimulated with IL-2 (10 ng/mL) for 24 hours, then co-incubated with UV-inactivated FcγRI-CHO cells and a gradient of Evunzekibart (0.002–50 nM) for 24–72 hours, with IL-2 added to maintain activation. Collect the supernatant and measure IFN-γ and granzyme B levels by ELISA.
Results: Evunzekibart significantly activated NK cells and increased IFN-γ and granzyme B levels. [1]

Methods: To investigate the antitumor effects of Evunzekibart, humanized 4-1BB knock-in mice (C57BL/6) were generated. A tumor model was established by subcutaneous transplantation of MC38 colon cancer cells. Following successful engraftment, Evunzekibart (10, 100, 200 μg) was administered intraperitoneally twice weekly for 3 weeks.
Results: Evunzekibart inhibited tumor growth in a dose-dependent manner, with complete inhibition observed at 200 μg, and improved mouse survival rates. [1]

Human

Monoclonal

Unconjugated